| __timestamp | Takeda Pharmaceutical Company Limited | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 612613000000 | 1244910 |
| Thursday, January 1, 2015 | 650773000000 | 5029636 |
| Friday, January 1, 2016 | 619061000000 | 4846776 |
| Sunday, January 1, 2017 | 628106000000 | 5329003 |
| Monday, January 1, 2018 | 717599000000 | 7121000 |
| Tuesday, January 1, 2019 | 964737000000 | 9128000 |
| Wednesday, January 1, 2020 | 875663000000 | 10731000 |
| Friday, January 1, 2021 | 886361000000 | 10701000 |
| Saturday, January 1, 2022 | 997309000000 | 16121000 |
| Sunday, January 1, 2023 | 1053819000000 | 37021000 |
| Monday, January 1, 2024 | 1053819000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants and emerging players is crucial. Takeda Pharmaceutical Company Limited, a global leader, and Viking Therapeutics, Inc., a promising biotech firm, offer a fascinating study in contrasts. From 2014 to 2023, Takeda's Selling, General, and Administrative (SG&A) expenses have shown a steady upward trajectory, peaking at over 1 trillion yen in 2023, reflecting a 72% increase from 2014. This growth underscores Takeda's expansive operational strategies and market reach. In contrast, Viking Therapeutics, with its more modest scale, saw its SG&A expenses rise from approximately 1.2 million USD in 2014 to 37 million USD in 2023, marking a staggering 2,900% increase. This dramatic rise highlights Viking's aggressive investment in growth and development. Notably, data for 2024 is incomplete, suggesting ongoing financial adjustments.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Takeda Pharmaceutical Company Limited
AbbVie Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Pfizer Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Takeda Pharmaceutical Company Limited vs Ascendis Pharma A/S: SG&A Expense Trends
Takeda Pharmaceutical Company Limited vs Opthea Limited: SG&A Expense Trends
Takeda Pharmaceutical Company Limited vs Viridian Therapeutics, Inc.: SG&A Expense Trends
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Walgreens Boots Alliance, Inc. or Viking Therapeutics, Inc.
Breaking Down SG&A Expenses: Verona Pharma plc vs Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Viking Therapeutics, Inc. or MiMedx Group, Inc.